
Quest Diagnostics (DGX) Stock Forecast & Price Target
Quest Diagnostics (DGX) Analyst Ratings
Bulls say
Quest Diagnostics Inc. demonstrates a strong financial outlook driven by robust growth in consumer-initiated testing, which saw revenue increases of nearly 50% in the fourth quarter and approximately 40% for the full fiscal year 2024. The company reported total revenue of $2.62 billion, reflecting a year-over-year increase of 14.5%, supported by a 13.9% rise in volumes. With expectations for expanding operating margins in 2025 and a strong cash flow from operations guidance of $1.45 billion, Quest Diagnostics is well-positioned for sustainable growth, bolstered by advancements in automation and AI initiatives that enhance operational efficiency.
Bears say
Quest Diagnostics Inc. faces significant financial challenges, primarily due to a projected headwind of approximately $0.20 per share related to investments in modernizing its IT infrastructure and compliance preparations for Laboratory Developed Testing (LDT) regulations. Additionally, the company is experiencing an anticipated $0.50 per share impact from higher year-over-year interest expenses, which further strains profitability. These factors, coupled with an uncertain hospital backdrop affecting reference test demand, contribute to a negative outlook for Quest Diagnostics’s stock.
This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Quest Diagnostics (DGX) Analyst Forecast & Price Prediction
Start investing in Quest Diagnostics (DGX)
Order type
Buy in
Order amount
Est. shares
0 shares